Who cares about phar­ma ESG ef­forts? Pa­tients and pa­tient groups do — and they want more, sur­vey finds

Even as en­vi­ron­men­tal, so­cial and gov­er­nance (ESG) ef­forts have fall­en out of fa­vor among some in­vestors and busi­ness lead­ers, the ma­jor­i­ty of pa­tients are still in­vest­ed in phar­ma ef­forts.

That’s es­pe­cial­ly true when it comes to the “S” or so­ci­etal ef­fect phar­ma com­pa­nies can have, ac­cord­ing to Pa­tientView’s lat­est ESG sur­vey pub­lished to­day.

Among the more than 830 glob­al pa­tient groups sur­veyed, 85% said phar­ma com­pa­nies’ im­pact on so­ci­ety is “im­por­tant” or “very im­por­tant” to the peo­ple and pa­tients they rep­re­sent. An­oth­er 78% said cor­po­rate gov­er­nance, and 64% said en­vi­ron­men­tal ef­fects were “im­por­tant” or “very im­por­tant” to pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER